DASER, antisense oligonucleotides as RNA-based therapy in endocrine resistance of breast cancer

Estrogen receptor–positive (ER+) breast cancer remains a major clinical challenge due to frequent resistance to endocrine therapies. The DASER project develops a novel antisense oligonucleotide targeting DSCAM-AS1, a tumor-specific lncRNA functionally interacting with ERα. By selectively disrupting this interaction, DASER modulates oncogenic estrogen signaling while preserving physiological activity, reducing invasiveness and metastatic potential, and offering a first-in-class RNA-based therapeutic opportunity.